News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
390,412 Results
Type
Article (26017)
Company Profile (346)
Press Release (364041)
Multimedia
Podcasts (95)
Webinars (12)
Section
Business (104623)
Career Advice (916)
Deals (17726)
Drug Delivery (51)
Drug Development (68200)
Employer Resources (78)
FDA (9275)
Job Trends (7944)
News (196576)
Policy (16223)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (1575)
Accelerated approval (28)
Adcomms (28)
Allergies (105)
Alliances (28714)
ALS (138)
Alzheimer's disease (1258)
Antibody-drug conjugate (ADC) (324)
Approvals (9487)
Artificial intelligence (353)
Autoimmune disease (145)
Automation (16)
Bankruptcy (158)
Best Places to Work (6903)
BIOSECURE Act (7)
Biosimilars (137)
Biotechnology (269)
Bladder cancer (152)
Brain cancer (59)
Breast cancer (598)
Cancer (4638)
Cardiovascular disease (296)
Career advice (766)
Career pathing (16)
CAR-T (274)
CDC (51)
Cell therapy (694)
Cervical cancer (27)
Clinical research (58621)
Collaboration (1430)
Company closure (3)
Compensation (774)
Complete response letters (50)
COVID-19 (2182)
CRISPR (91)
C-suite (634)
Cystic fibrosis (128)
Data (5511)
Decentralized trials (1)
Denatured (17)
Depression (102)
Diabetes (348)
Diagnostics (3126)
Digital health (16)
Diversity (6)
Diversity, equity & inclusion (18)
Drug discovery (224)
Drug pricing (83)
Drug shortages (8)
Duchenne muscular dystrophy (224)
Earnings (42161)
Editorial (40)
Employer branding (8)
Employer resources (71)
Events (68431)
Executive appointments (704)
FDA (11560)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1151)
Gene editing (194)
Generative AI (34)
Gene therapy (544)
GLP-1 (714)
Government (2419)
Grass and pollen (4)
Guidances (240)
Healthcare (10120)
HIV (44)
Huntington's disease (43)
IgA nephropathy (82)
Immunology and inflammation (252)
Immuno-oncology (61)
Indications (93)
Infectious disease (2415)
Inflammatory bowel disease (183)
Inflation Reduction Act (11)
Influenza (87)
Intellectual property (195)
Interviews (172)
IPO (9377)
IRA (24)
Job creations (1394)
Job search strategy (640)
JPM (51)
Kidney cancer (16)
Labor market (39)
Layoffs (370)
Leadership (23)
Legal (2295)
Liver cancer (80)
Longevity (12)
Lung cancer (635)
Lymphoma (350)
Machine learning (33)
Management (31)
Manufacturing (491)
MASH (143)
Medical device (4081)
Medtech (4094)
Mergers & acquisitions (9100)
Metabolic disorders (951)
Multiple sclerosis (145)
NASH (14)
Neurodegenerative disease (267)
Neuropsychiatric disorders (78)
Neuroscience (2295)
Neurotech (1)
NextGen: Class of 2026 (2974)
Non-profit (1700)
Now hiring (38)
Obesity (435)
Opinion (199)
Ovarian cancer (162)
Pain (136)
Pancreatic cancer (212)
Parkinson's disease (255)
Partnered (14)
Patents (364)
Patient recruitment (403)
Peanut (53)
People (33171)
Pharmaceutical (50)
Pharmacy benefit managers (13)
Phase 1 (19384)
Phase 2 (26228)
Phase 3 (18809)
Pipeline (4152)
Policy (169)
Postmarket research (1594)
Preclinical (7886)
Press Release (42)
Prostate cancer (227)
Psychedelics (50)
Radiopharmaceuticals (281)
Rare diseases (758)
Real estate (2196)
Recruiting (31)
Regulatory (14817)
Reports (24)
Research institute (1729)
Resumes & cover letters (149)
Rett syndrome (25)
RNA editing (21)
RSV (74)
Schizophrenia (132)
Series A (203)
Series B (148)
Service/supplier (2)
Sickle cell disease (90)
Special edition (19)
Spinal muscular atrophy (125)
Sponsored (26)
Startups (2339)
State (1)
Stomach cancer (17)
Supply chain (54)
Tariffs (34)
The Weekly (77)
Vaccines (918)
Venture capital (80)
Weight loss (247)
Women's health (35)
Worklife (8)
Date
Today (68)
Last 7 days (421)
Last 30 days (1499)
Last 365 days (22895)
2026 (2167)
2025 (23174)
2024 (25960)
2023 (28809)
2022 (34818)
2021 (36552)
2020 (32001)
2019 (23486)
2018 (17356)
2017 (19288)
2016 (17567)
2015 (20650)
2014 (15111)
2013 (11171)
2012 (11513)
2011 (11392)
2010 (10707)
Location
Africa (363)
Alabama (67)
Alaska (3)
Arizona (106)
Arkansas (6)
Asia (24786)
Australia (4413)
California (8629)
Canada (2193)
China (961)
Colorado (325)
Connecticut (336)
Delaware (310)
Europe (55683)
Florida (1191)
Georgia (247)
Hawaii (3)
Idaho (25)
Illinois (548)
India (42)
Indiana (316)
Iowa (15)
Japan (344)
Kansas (87)
Kentucky (23)
Louisiana (8)
Maine (60)
Maryland (941)
Massachusetts (6643)
Michigan (131)
Minnesota (315)
Mississippi (3)
Missouri (45)
Montana (20)
Nebraska (7)
Nevada (60)
New Hampshire (33)
New Jersey (2307)
New Mexico (15)
New York (2304)
North Carolina (975)
North Dakota (6)
Northern California (4321)
Ohio (216)
Oklahoma (13)
Oregon (27)
Pennsylvania (1509)
Puerto Rico (10)
Rhode Island (28)
South America (464)
South Carolina (12)
Southern California (3321)
Tennessee (75)
Texas (1221)
United States (29270)
Utah (144)
Virginia (185)
Washington D.C. (47)
Washington State (694)
West Virginia (1)
Wisconsin (89)
390,412 Results for "immune onc therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
December 10, 2025
·
14 min read
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
December 11, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas
January 20, 2026
·
3 min read
Press Releases
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
November 19, 2025
·
11 min read
Biotech Bay
Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced the company will present Phase 1b interim data for IO-202 in patients with chronic myelomonocytic leukemia (CMML) at the 2024 European Hematology Association (EHA) Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
May 14, 2024
·
5 min read
Press Releases
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
December 8, 2025
·
14 min read
Press Releases
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
October 28, 2025
·
11 min read
Biotech Bay
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
February 21, 2024
·
6 min read
Drug Development
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced a Phase 1b/2 clinical trial collaboration with Roche to evaluate Immune-Onc’s IO-108, a first-in-class antibody targeting LILRB2 (also known as ILT4), in combination with Roche’s atezolizumab and bevacizumab for the first-line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC).
February 20, 2024
·
6 min read
Drug Development
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. announced the company will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
June 14, 2024
·
6 min read
1 of 39,042
Next
